Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab

A Cingolani; A M Tummolo; G Montemurro; E Gremese; L Larosa; M C Cipriani; G Pasciuto; R Liperoti; R Murri; T Pirronti; R Cauda; M Fantoni; for COVID 2 Columbus Working Group

doi:10.1007/s15010-020-01476-7

Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab

Infection. 2020 Oct;48(5):767-771. doi: 10.1007/s15010-020-01476-7. Epub 2020 Jul 8.

Authors

A Cingolani^{1

2}, A M Tummolo^{3

4}, G Montemurro⁵, E Gremese^{5

6}, L Larosa⁷, M C Cipriani⁸, G Pasciuto⁵, R Liperoti^{8

6}, R Murri^{1

2}, T Pirronti^{7

9}, R Cauda^{1

2}, M Fantoni^{1

2}; for COVID 2 Columbus Working Group

Collaborators

for COVID 2 Columbus Working Group:
A Bellieni, V Brandi, A Calabrese, M R Calvello, A Ciccullo, A Cingolani, M C Cipriani, G Corbo, C Falsiroli, M Fantoni, E Intini, G Landi, P M Leone, R Liperoti, F Macagno, I Martis, G Montemurro, R Murri, C Pais, G Pasciuto, A Potenza, S Salini, J Simonetti, E Taddei, M Tosato, A M Tummolo, F Varone, G Ventura, M Siciliano

Affiliations

¹ Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
² Dipartimento di Sicurezza e Bioetica, Università Cattolica S. Cuore, Milan, Italy.
³ Dipartimento di Scienze dell'invecchiamento, Fondazione Policlinico Gemelli IRCCS, Rome, Italy. anita.tummolo@gmail.com.
⁴ Division of Infectious Diseases, Covid 2 Columbus, Fondazione Policlinico Gemelli, IRCCS, Università Cattolica S. Cuore, L.go A. Gemelli 8, 00167, Rome, Italy. anita.tummolo@gmail.com.
⁵ Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
⁶ Dipartimento di Scienze Geriatriche e Ortopediche, Università Cattolica S. Cuore, Milan, Italy.
⁷ Dipartimento di Diagnostica per immagini, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
⁸ Dipartimento di Scienze dell'invecchiamento, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
⁹ Dipartimento di Scienze Radiologiche e Ematologiche, Università Cattolica S. Cuore, Milan, Italy.

Abstract

A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.

Keywords: Baricitinib; COVID-19; Immunotherapy; SARS-CoV-2; Sarilumab.

Publication types

Case Reports

MeSH terms

Acute Disease
Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Antiviral Agents / therapeutic use*
Azetidines / therapeutic use*
Azithromycin / therapeutic use
Betacoronavirus / drug effects
Betacoronavirus / pathogenicity*
COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / physiopathology
Coronavirus Infections / virology
Drug Combinations
Drug Repositioning
Humans
Hydroxychloroquine / therapeutic use
Lopinavir / therapeutic use
Male
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / physiopathology
Pneumonia, Viral / virology
Purines
Pyrazoles
Respiratory Insufficiency / drug therapy*
Respiratory Insufficiency / physiopathology
Respiratory Insufficiency / virology
Ritonavir / therapeutic use
SARS-CoV-2
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antiviral Agents
Azetidines
Drug Combinations
Purines
Pyrazoles
Sulfonamides
lopinavir-ritonavir drug combination
Lopinavir
Hydroxychloroquine
Azithromycin
baricitinib
sarilumab
Ritonavir